Taylor Cottrill Erickson & Associates Inc. Sells 1,700 Shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY)

Taylor Cottrill Erickson & Associates Inc. lowered its position in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 6.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,490 shares of the company’s stock after selling 1,700 shares during the quarter. Taylor Cottrill Erickson & Associates Inc.’s holdings in Roche Holdings AG Basel were worth $860,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of RHHBY. Advisors Asset Management Inc. bought a new position in shares of Roche Holdings AG Basel during the 1st quarter worth about $144,000. Beck Mack & Oliver LLC bought a new position in shares of Roche Holdings AG Basel during the 1st quarter worth about $203,000. South Texas Money Management Ltd. bought a new position in shares of Roche Holdings AG Basel during the 1st quarter worth about $215,000. MAI Capital Management bought a new position in shares of Roche Holdings AG Basel during the 1st quarter worth about $220,000. Finally, Dearborn Partners LLC boosted its position in shares of Roche Holdings AG Basel by 11.9% during the 1st quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock worth $321,000 after purchasing an additional 992 shares in the last quarter. 0.30% of the stock is currently owned by institutional investors and hedge funds.

OTCMKTS RHHBY traded up $0.12 during trading hours on Wednesday, hitting $34.01. The company’s stock had a trading volume of 545,709 shares, compared to its average volume of 962,746. Roche Holdings AG Basel ADR has a 52 week low of $28.74 and a 52 week high of $35.90. The stock has a market capitalization of $232.40 billion, a P/E ratio of 14.66, a PEG ratio of 2.20 and a beta of 0.48. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.40 and a quick ratio of 1.11. The company’s 50-day moving average price is $34.42.

A number of equities analysts have recently issued reports on RHHBY shares. Zacks Investment Research raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research report on Tuesday, July 9th. UBS Group raised shares of Roche Holdings AG Basel from a “neutral” rating to a “buy” rating in a research report on Friday, July 26th. Deutsche Bank raised shares of Roche Holdings AG Basel from a “hold” rating to a “buy” rating in a research report on Thursday, June 20th. Finally, Liberum Capital cut shares of Roche Holdings AG Basel from a “buy” rating to a “hold” rating in a research report on Thursday, June 20th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. Roche Holdings AG Basel presently has a consensus rating of “Buy” and an average price target of $37.00.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

See Also: Tariff

Institutional Ownership by Quarter for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.